Speakers - Sachs Associates

More documents

Recommendations

Info

<strong>Speakers</strong> Martin Welschof, CEO, Opsona Therapeutics Ltd Martin is the CEO of Opsona Therapeutics Ltd, a leading immunology drug development company in Dublin focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases. Before Opsona he was the MD & Co-founder of Affitech A/S, a biopharmaceutical company focused on the discovery & development of human antibodies, listed on the Nasdaq OMX Copenhagen stock exchange. Affitech AS was transformed through a reverse merger in 2009 with Pharmexa A/S, listed on the Copenhagen stock exchange. In 2010 he was a key resource in implementing a strategic partnership with the Russian Pharmaceutical IBC Generium (worth up to €24.6m) & secured strategic investment from Trans Nova (€20.9m). Prior to Affitech AS, he was Director of Technology at Axaron Bioscience AG, Heidelberg, Germany during the Company’s start-up phase. During a portion of this period was an expatriate at the parent company, LYNX Therapeutics Inc., Hayward, California, contributing to the process development of LYNX massive parallel cloning & sequencing technologies. Matthias Steger, Global Head Research & Technology Partnering, Roche Matthias is Global Head Research & Technology Partnering at Roche; he holds a PhD in Medicinal Chemistry from the University of Sussex, UK, and an MBA from the University of St Gallen, Switzerland. Prior to joining Roche in his current role, Dr Steger was a Pharma/Biotech analyst at the investment bank Kepler Equities and was Head of Chemical Technologies at Axovan, a biotech company which was subsequently acquired by Actelion, Basel, Switzerland. He began his career in the pharmaceutical industry at Roche in 1999 as Laboratory Head in Medicinal Chemistry.. Mike Romanos, CEO, Crescendo Biologics Mike is CEO and founder of Crescendo Biologics, an innovative transgenic antibody fragment company based in Cambridge, UK. He has 25 years’ biotech and pharmaceutical industry experience in biologic and NCE drug discovery across most therapeutic areas, starting with Wellcome Biotech in the 1980s. Previous to his current role, Mike held leadership positions for over 10 years in GlaxoSmithKline R&D, building and managing global Discovery organisations that made a major impact in targets, technology and pipeline projects. In particular, Mike established GSK’s antibody lead discovery capability which generated a pipeline of in-house monoclonal antibodies, several of which are in clinical development. Mike holds a degree in Natural Sciences from Cambridge University, a PhD in Molecular Virology from Imperial College, and undertook postdoctoral research in Virology at the MRC’s National Institute for Medical Research and in Yeast Biotechnology at Leicester Biocentre. He is currently a panel member of the MRC’s Developmental Pathway Funding Scheme, which funds translational studies through preclinical and early clinical development, and a Fellow of the Society of Biology. Naveed Siddiqi, Partner, Phase4 Ventures Limited Naveed is a Partner of Phase4 Ventures with over 11 years experience of investing in healthcare companies in US, Europe and Asia. Naveed worked for Nomura and was actively involved with many of Nomura Phase4 Venture’s private investments including Pharmion and Paratek. He has taken Board observer roles on the Boards of several companies. Prior to joining Nomura’s healthcare investment business, he spent 5 years advising management teams and companies on buy-outs, cross border M&A, private and public company offerings in biotechnology and other sectors whilst at Nomura and EFG Group. Naveed holds a degree in Medicine from Guy’s Hospital, London and worked in the UK’s National Health Service as a doctor. He is also qualified as a chartered accountant whilst at KPMG and holds a Diploma in Company Direction from the Institute of Directors. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
<strong>Speakers</strong> Paul Higham, Managing Director, immatics Biotechnologies Paul was appointed as CEO of immatics in August 2008. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland. Prior to joining Ark Therapeutics in 2001, Paul Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc from 1996 to 2001, where he covered all aspects of business development, strategic marketing and sales. From 1985 to 1996, after completing his studies in Applied Biology, he held various sales and marketing positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark. Patrik Frei, CEO, Venture Valuation Patrik is founder and CEO of Venture Valuation AG, Switzerland. Patrik graduated from the Business University of St. Gallen and completed his Ph.D thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, EPFL Lausanne. Prior to forming Venture Valuation, Patrik was CFO of a logistic company and worked for several international corporations: LeCroy (Geneva, New York), Hans Merensky Holding (South Africa) and Swatch Group – EM Microelectronic (Marin). Patrik is a board member and one of the original founders of ineo, a holding company of the Swiss dental implant VCbacked firm Thommen Medical and a board member of Ophthalmopharma, a Swiss based biotech ophthalmology company. Patrik’s articles have been published in a number of scientific journals including “Nature Biotechnology”, “Chimia” and other business publications (“Starting a Business in the Life Sciences: From Idea to Market” and “Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies”). He has also lectured at Seoul National University, South Korea and Danube University Krems, Austria and presented at numerous Valuation workshops around the world. More recently, Patrik was named as one of the 20 most influential people in the Swiss Life Sciences Industry by Bilan, a Swiss Business Journal along with other noteworthy individuals such as Ernesto Bertarelli, Daniel Vasella and Henry B. Meier. Specialties: Finance, valuation, merger and acquisition, reporting of high growth companies in the VC and private equity area. Peter E. Burckhardt, CEO, EVA the Basel Life Sciences Start-up agency Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups. Peter is CEO of “EVA the Basel Life Sciences Start-up agency”. This company was founded in 1996 with the aim to support life sciences start-ups with coaching, access to a high value network and providing seed money. In addition he is CEO of the BASEL INCUBATOR, which he helped to establish 2 years ago. The BASEL INCUBATOR is a joint venture of the University of Basel, the University of Applied Sciences of Northwestern Switzerland (FHNW) and the Canton of Basel-Stadt. To complement his activities, Peter is the president of the BioValley Business Angel Club, the only Business Angel’s Club in Switzerland focusing entirely on life sciences / MedTech. Peter has a PhD in chemistry from the University of Basel and joined Ciba-Geigy / Novartis 1984 as a research chemist. Throughout his professional career he had managerial positions with worldwide responsibility in technical development, regulatory affairs, manufacturing, production and communication and was the CEO of the subsidiary of a sector of Novartis in Germany. He joined EVA in 2006. Peter Stein, Chairman & CEO, Norgine Peter is the Chairman and Chief Executive and principal shareholder of Norgine, an independent specialty pharmaceutical company with operations throughout Europe. Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor. Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2: B I O T E C H I N E U R O P E I N V
Page 3 and 4: Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17: Speakers Marcel Zwaal, CBO, DCPrime
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70:
CONTACT Tom Johnston Chief Executiv
Page 71 and 72:
CONTACTS Aaron Powers President Dav
Page 73 and 74:
CONTACTS General and Media Contact
Page 75 and 76:
CONTACTS Martin Welschof Chief Exec
Page 77 and 78:
CONTACTS Carlos Buesa Chief Executi
Page 79 and 80:
CONTACTS Nick McCooke Chief Executi
Page 81 and 82:
CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84:
CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86:
CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88:
ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90:
CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92:
CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94:
CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96:
CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98:
CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100:
CONTACTS Piers Morgan Chief Financi
Page 101 and 102:
CONTACT Jakob Knudsen Chief Executi
Page 103 and 104:
CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106:
Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?